Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial
Because peace of mind matters
Medicare will begin covering GLP-1 medications for obesity through the Medicare GLP-1 Bridge program starting July 1, 2026, offering eligible beneficiaries access for $50 per month
GLP-1 tapering and long-term weight management If youre taking a GLP-1 for type 2 diabetes, you will likely stay on your maintenance dose unless your doctor recommends otherwise
485,486 This affects the synthesis of triacylglycerol (TAG), phosphatidic acid (di-P PA), and diacylglycerol (DAG) in the liver
Millions of people are already used to the routine of injecting themselves once a week